Improved neuroprotective effects of resveratrol-loaded polysorbate 80-coated poly(lactide) nanoparticles in MPTP-induced Parkinsonism.
OBJECTIVE
This study investigated the neuroprotective effects of resveratrol (RVT)-loaded polysorbate 80 (PS80)-coated poly(lactide) nanoparticles in a mouse model of Parkinson's disease (PD), and compared these effects with those from bulk RVT.


METHODS
C57BL/6 mice received for 15 days RVT intraperitoneally (nanoparticulate or non-nanoparticulate), as well as single intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a neurotoxin that damages dopaminergic neurons and induces PD-related symptoms.


RESULTS
MPTP induced significant impairments on olfactory discrimination and social recognition memory, as well as caused striatal oxidative stress and reduced the expression of tyrosine hydroxylase in striatum. RVT-loaded nanoparticles (but not bulk) displayed significant neuroprotection against MPTP-induced behavioral and neurochemical changes.


CONCLUSIONS
These results point to RVT-loaded poly(lactide)-nanoparticles coated with PS80 a promising nanomedical tool and adjuvant therapy for PD.
Department of Pharmacy, Laboratory of Pharmaceutical Nanotechnology, Universidade Estadual do Centro-Oeste/UNICENTRO, Rua Simeão Camargo Varela de Sá, 03, 85040-080, Guarapuava, PR, Brazil.
Gabriela
G
da Rocha Lindner
Danúbia
D
Bonfanti Santos
Dirleise
D
Colle
Eduardo Luiz
EL
Gasnhar Moreira
Rui
R
Daniel Prediger
Marcelo
M
Farina
Najeh Maissar
NM
Khalil
Rubiana
R
Mara Mainardes
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D000818:Animals; D000975:Antioxidants / Q000008:administration & dosage / Q000627:therapeutic use; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology; D059290:Dopaminergic Neurons / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D004337:Drug Carriers / Q000737:chemistry*; D008297:Male; D008568:Memory / Q000187:drug effects; D051379:Mice; D008810:Mice, Inbred C57BL; D018696:Neuroprotective Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D055696:Olfactory Perception / Q000187:drug effects; D018384:Oxidative Stress / Q000187:drug effects; D010302:Parkinson Disease, Secondary / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology; D011091:Polyesters / Q000737:chemistry*; D011136:Polysorbates / Q000737:chemistry*; D000077185:Resveratrol; D013267:Stilbenes / Q000008:administration & dosage* / Q000627:therapeutic use
D000975:Antioxidants; D004337:Drug Carriers; D018696:Neuroprotective Agents; D011091:Polyesters; D011136:Polysorbates; D013267:Stilbenes; C033616:poly(lactide); D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D000077185:Resveratrol
Parkinson's disease; antioxidant; nanoparticles; polysorbate 80; resveratrol